DOCSLIB.ORG

Greener Hospitals U R T EN Z S T F a H C S N E S Improving IS W Environmental Performance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Greener Hospitals U R T EN Z S T F a H C S N E S Improving IS W Environmental Performance please feel free to visit our website atwww.bms.com. tovisitourwebsite please feelfree our policiesandprocedures, Squibb, wouldlikeadditionalinformationonBristol-Myers you If www.wzu.uni-augsburg.de. at ScienceCenterplease visitourwebsite additionalinformationontheEnvironmental For ispossible. Thus, innovation practicalapplications. involving useful forprojects industrysectors,whichisparticularly various withdecision-makersfrom us todealdirectly WEC enables The partnershipwiththe Umwelt. Wissenschaftszentrum located adjacenttothe Centeris Environment World ofthe office thattheEuropean for ourwork a majoradvantage itis Therefore, understanding oftechnicalandindustrialissues. athorough science requires inenvironment Progress the sustainablehandlingofsubstances,materialsandenergy. foraspecifiedperiodontopicswithinthecontextofourcentraltheme - towork Umwelt Wissenschaftszentrum setupat are groups usuallytakenforgranted.Research which are methods, to aquestioningofthetraditionalacademicdivisionsandfield-specificworking otherfieldsofstudyshouldlead withscientistsfrom The exchange staff. university our own othercountrieswillcomplementthepotentialof andfrom otheruniversities scientists from The participationof fields. different from thecollaborationofresearchers studied through topicscanonlybefittingly dialogue.Environmental ofinterdisciplinary energy productive focusingonthe are this,we achieve To Studies. inthefieldofEnvironmental developments andtechnological research innovative aimistostimulatecross-disciplinary, Our research. environmental ofinterdisciplinary projects forinternationalco-operative 'crossroads' expertsand acenterand international meeting-placeforselectedhigh-rankingenvironmental isan University Augsburg ScienceCenter)at (Environment Umwelt Wissenschaftszentrum The Umwelt/WZU Wissenschaftszentrum ISBN 3-00-012582-5 Greener Hospitals W ISSENSCHAFTSZ ENTRUMU MWELT WZU With support from: Bristol-Myers Squibb Company Squibb supportWith Bristol-Myers from: Germany Augsburg, ScienceCenter, Environment by: Edited Greener Hospitals Greener Performance Environmental Improving Greener Hospitals Notes We would like to thank all the individuals and organizations that contributed to this manual. Reviewers included: Kai Abelkis - Boulder Community Hospital, Boulder, Colorado; Laura Brannen - Hospitals for a Healthy Environment, Lebanon, New Hampshire; Bonnie Eskenazi - The Deirdre Imus Environmental Center for Pediatric Oncology, Hackensack, New Jersey; John N. Gamble - The UTMD Anderson Cancer Center, Houston, Texas; Jill Kavoukian - Stony Brook University, Stony Brook, New York; Dr. Klaus Kümmerer - University Hospital, Freiburg Institute for Environmental Medicine and Hospital Epidemiology, Germany; Melissa Leone RN, BSN - Apria Healthcare, Hamden, Connecticut; Dr. Uta Müller - Institut für Management und Umwelt- schutz; Martin Scherrer - University Hospital Freiburg. Institute for Environmental Medicine and Hospital Epidemiology, Germany; Isabelle Secher - World Environment Center, Europe, Augsburg, Germany; Karen Shapiro - Tellus Institute, Boston, Massachusetts; Dr. Francesco Violante - University of Bologna, Bologna, Italy; Marian Condon - College Park, Maryland; Charlotte Burg - Gentofte County Hospital, Hellerup, Denmark; Bo Jonoe - Sonderbrog Hospital, Sonderbrog, Denmark; Erica Stewart and Kathy Gerwig, Kaiser Permanente, Oakland, California; the American Society for Healthcare Environmental Services, Chicago, Illinois; Klaus Meier - European Society of Oncology Pharmacy, Hamburg, Germany; James G. Veras - World Environment Center, Executive Vice President Emeritus, Palm Beach, U.S.. This manual has been prepared by Wissenschaftszentrum Umwelt, Augsburg, Germany, with support of Bristol-Myers Squibb. Edited by: Wissenschaftszentrum Umwelt University Augsburg, Germany Printer: OrtmannTeam GmbH, 81379 Munich, Germany Designed by: Cordula Schwab, Art and Design, Augsburg, Germany Coordinated by: Prof. Dr. Armin Reller, Chairman Wissenschaftszentrum Umwelt, Augsburg, Germany Supported by: Bristol-Myers Squibb Company Ludwig Metz and Team ISBN 3-00-012582-5 Greener Hospitals As a leading pharmaceutical company, Bristol-Myers Squibb’s mission is …to extend and en- hance human life. The company’s core values, as embodied in the Bristol-Myers Squibb Pledge, focus on sustaining and improving the lives of people throughout the world. We feel that our support of this document is tangible evidence of our firm commitment to be a global environ- mental leader while helping healthcare facilities become more aware of their environmental impacts and responsibilities. For more information on Bristol-Myers Squibb Company, please visit our website at www.bms.com. For more information on the Wissenschaftszentrum Umwelt University Augsburg, Germany, please visit their website at www.wzu.uni-augsburg.de. For additional copies, please contact: D. Pulkinen Bristol-Myers Squibb P.O. Box 4755 Syracuse, NY 13221-4755 Telephone: + 315-432-2997 Fax: + 315-432-2836 All rights reserved Bristol-Myers Squibb Co. This publication is protected by Copyright. No part of this publication may be reproduced. This manual sets forth broadbased general guidance relating to environmental management systems, and does not address all issues in any given country. With regards to country-specific legal regulatory requirements, it is the reader’s responsibility to seek competent professional guidance. Editors, coordinators, supporters, suppliers and reviewers do not assume any liability. This manual has been prepared with an environmental focus throughout the production process. It is printed on paper made of 100 percent post consumer waste fiber, processed chlorine free, using vegetable-based inks. 1 EnvironmentalSpecific Areas for Potential Improvement Management for Healthcare Facilities Forward Throughout the world, hospitals and other healthcare facilities are dedicated to providing innovative and compassionate patient care that meets high standards of quality in a cost-effective manner. How- ever, in fulfilling this important mission to care for patients, healthcare facilities have an impact on the natural environment. Over the past few years, regulatory agencies and local communities have pushed for greater environmental controls within the healthcare setting. From energy conservation to the proper disposal of medical waste and the safe handling of highly potent pharmaceuticals, healthcare facilities are discovering that the adage “do no harm” is applicable not only to their patients but to the natural environment and communities around them. Healthcare facilities across the globe are rising to this challenge by identifying and reducing the negative enviromental impact of their operations. In particular, hospitals, clinics, and doctors’ offices are adopting formal environmental management systems and sharing best practices that have been successfully used by other organizations in the healthcare sector. This manual provides practical advice to help healthcare facilities improve their environmental management systems and performance. By clearly outlining the benefits of sharing best practices and developing formal environmental management systems, we feel that this document will better prepare healthcare facilities to meet the rising expectations of regulators and their local communi- ties. Key features of this manual include: ½ Internet addresses for more than 40 sites that provide additional background information and case studies from Europe, Asia, and the United States Self-assessment checklists covering: Environmental management systems Laboratory, cleaning, laundry, kitchen Waste management Energy management Hazardous substances Water management Wastewater management Air emissions Purchasing and material management Due to space limitations, this document does not address employee health and safety issues. However, we recognize that protecting healthcare workers is an important responsibility that is connected not only to environmental stewardship, but also to the mission of healthcare facilities. Prof. Dr. Armin Reller, Chairman Wissenschaftszentrum Umwelt, Augsburg, Germany 2 Table of Contents 1. Introduction 1.1. Why an Environmental Management System is Important for Healthcare Facilities page 5 1.2. What is an Environmental Management System and How Can It Benefit Healthcare Facilities and Their Patients? page 5 1.3. What is Covered in the Manual? page 6 2. Hospitals Today 2.1. Stakeholders in Hospitals page 7 2.2. Hospitals as “Role Models” page 8 2.3. Environmental Impacts and Prevention page 8 2.4. Evaluating and Benchmarking Environmental Impact page 9 2.4.1. Influence of Hospital Characteristics on Environmental Impact page 9 2.5. Environmental Impacts page 10 2.5.1. Energy Consumption page 10 2.5.2. Water Consumption page 12 2.5.3. Waste Management page 13 3. Environmental Management System 3.1. What is an Environmental Management System? page 15 3.2. Eco-Management and Audit Scheme (EMAS) and International Standards Organization (ISO) page 15 3.3. ISO 14001 and Aspects Analysis page 15 3.3.1. Key Elements of ISO 14001 page 15 3.3.2. Aspects Analysis page 18 3.3.2.1. Categories of Environmental Aspects page 18 3.3.2.2. Aspects Analysis Methodology page 18 3.4. Web Addresses: Environmental Management Systems page 20 4. Implementing an Environmental Management System 4.1. General page 21 4.2. Practical Tips page 21 4.3. Environmental Management System Checklists page 23 4.4. Training page 23 3 SpecificTable of AreasContents for
Load more

Recommended publications
  • Preventive Health Care
    PREVENTIVE HEALTH CARE DANA BARTLETT, BSN, MSN, MA, CSPI Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevire, Lippincott, and Thieme. He has written widely on the subject of toxicology and was recently named a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center and is actively involved in lecturing and mentoring nurses, emergency medical residents and pharmacy students. ABSTRACT Screening is an effective method for detecting and preventing acute and chronic diseases. In the United States healthcare tends to be provided after someone has become unwell and medical attention is sought. Poor health habits play a large part in the pathogenesis and progression of many common, chronic diseases. Conversely, healthy habits are very effective at preventing many diseases. The common causes of chronic disease and prevention are discussed with a primary focus on the role of health professionals to provide preventive healthcare and to educate patients to recognize risk factors and to avoid a chronic disease. nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities.
    [Show full text]
  • PREVENTIVE CARE SERVICES Policy Number: PREVENTIVE 006.50 T0 Effective Date: June 1, 2018
    UnitedHealthcare® Oxford Clinical Policy PREVENTIVE CARE SERVICES Policy Number: PREVENTIVE 006.50 T0 Effective Date: June 1, 2018 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Breast Imaging for Screening and Diagnosing CONDITIONS OF COVERAGE ...................................... 1 Cancer BENEFIT CONSIDERATIONS ...................................... 2 Cardiovascular Disease Risk Tests COVERAGE RATIONALE ............................................. 2 Cytological Examination of Breast Fluids for Cancer DEFINITIONS .......................................................... 6 Screening APPLICABLE CODES ................................................. 8 Genetic Testing for Hereditary Cancer REFERENCES .......................................................... 50 POLICY HISTORY/REVISION INFORMATION ................ 51 Par Gastroenterologists Using Non-Par Anesthesiologists: In-Office & Ambulatory Surgery Centers Preventive Medicine and Screening Vaccines INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific
    [Show full text]
  • Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
    www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222.
    [Show full text]
  • A Screening-Based Approach to Circumvent Tumor Microenvironment
    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
    [Show full text]
  • 2020 Complete Guide to Health Benefit Plans
    FOR BUSINESSES WITH 1–50 EMPLOYEES 2020 health plan guide 1 Table of contents ABOUT PREMERA ............................ 3 Why businesses choose Premera .................4 WE’RE IN YOUR CORNER ..................... 5 Medical plan support programs ...................5 PROVIDER NETWORKS ....................... 6 Provider network options .........................7 MEDICAL AND DENTAL PLANS ............... 8 Medical plan snapshot ..........................10 Adult vision ....................................12 Medical plans with Family Dental ................13 Adult dental plans ..............................14 Dental plan snapshot ...........................15 Adult Dental Optima™ ...........................16 Adult Dental Optima Voluntary™ .................18 Dental options and requirements ................20 2 We care for our customers The customer is at the center of all we do—that’s why we offer plans that help you keep control of your expenses while giving your employees access to quality and affordable care. 3 Why businesses choose Premera Network strength provides choice and savings • We offer a variety of provider network options so you can choose the level of access that works best for the needs of your employees. Well-rounded benefits package • We make it easy for you to attract and retain the best talent with appealing benefits packages that support the whole health of your employees. • Choose from a range of plans to find the right balance that best fits the needs and budget for both your business and your employees. Tools and programs for employees • Our built-in support programs encourage your employees to engage in their healthcare, leading to healthier, happier employees. • Online tools and apps help your employees find doctors, compare costs of services and medications, access pharmacy information, and review claims. Administrative ease and support • Integrate dental and vision with your medical and pharmacy plans and simplify your work by dealing with only one health plan for all your healthcare administration.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,039,940 Perrault Et Al
    US0060399.40A United States Patent (19) 11 Patent Number: 6,039,940 Perrault et al. (45) Date of Patent: Mar. 21, 2000 54) INHERENTLY ANTIMICROBIAL 5,563,056 10/1996 Swan et al.. QUATERNARY AMINE HYDROGEL WOUND 5,599.321 2/1997 Conway et al.. DRESSINGS 5,624,704 4/1997 Darouiche et al.. 5,670.557 9/1997 Dietz et al.. 75 Inventors: James J. Perrault, Vista, Calif.; 5,674.561 10/1997 Dietz et al.. Cameron G. Rouns, Pocatello, Id. 5,800,685 9/1998 Perrault. FOREIGN PATENT DOCUMENTS 73 Assignee: Ballard Medical Products, Draper, Utah 92/06694 4/1992 WIPO. WO 97/14448 4/1997 WIPO. 21 Appl. No.: 09/144,727 OTHER PUBLICATIONS 22 Filed: Sep. 1, 1998 I. I. Raad, “Vascular Catheters Impregnated with Antimi crobial Agents: Present Knowledge and Future Direction,” Related U.S. Application Data Infection Control and Hospital Epidemiology, 18(4): 63 Continuation-in-part of application No. 08/738,651, Oct. 28, 227–229 (1997). 1996, Pat. No. 5,800,685. R. O. Darouiche, H. Safar, and I. I. Raad, “In Vitro Efficacy of Antimicrobial-Coated Bladder Catheters in Inhibiting 51) Int. Cl." .......................... A61K31/785; A61F 13/00 Bacterial Migration along Catheter Surface,” J. Infect. Dis., 52 U.S. Cl. ..................................... 424/78.06; 424/78.08; 176: 1109-12 (1997). 424/78.35; 424/78.37; 424/443; 424/445 W. Kohen and B. Jansen, “Polymer Materials for the Pre 58 Field of Search ..................................... 424/443, 445, vention of Catheter-related Infections.” Zbl Bakt., 283: 424/78.06, 78.07, 78.08, 78.35, 78.37 175-186 (1995).
    [Show full text]
  • A Neural Network Analysis of Behavioral Habits and Chronic Diseases
    healthcare Article Preventive Healthcare: A Neural Network Analysis of Behavioral Habits and Chronic Diseases Viju Raghupathi 1,* and Wullianallur Raghupathi 2 1 Koppelman School of Business, Brooklyn College of the City University of New York, Brooklyn, NY 11210, USA 2 Gabelli School of Business, Fordham University, New York, NY 10058, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-718-951-5000 Academic Editor: Sampath Parthasarathy Received: 30 November 2016; Accepted: 19 January 2017; Published: 6 February 2017 Abstract: The research aims to explore the association between behavioral habits and chronic diseases, and to identify a portfolio of risk factors for preventive healthcare. The data is taken from the Behavioral Risk Factor Surveillance System (BRFSS) database of the Centers for Disease Control and Prevention, for the year 2012. Using SPSS Modeler, we deploy neural networks to identify strong positive and negative associations between certain chronic diseases and behavioral habits. The data for 475,687 records from BRFS database included behavioral habit variables of consumption of soda and fruits/vegetables, alcohol, smoking, weekly working hours, and exercise; chronic disease variables of heart attack, stroke, asthma, and diabetes; and demographic variables of marital status, income, and age. Our findings indicate that with chronic conditions, behavioral habits of physical activity and fruit and vegetable consumption are negatively associated; soda, alcohol, and smoking are positively associated; and income and age are positively associated. We contribute to individual and national preventive healthcare by offering a portfolio of significant behavioral risk factors that enable individuals to make lifestyle changes and governments to frame campaigns and policies countering chronic conditions and promoting public health.
    [Show full text]
  • Identification of Drug Candidates That Enhance Pyrazinamide Activity from a Clinical Drug Library
    bioRxiv preprint doi: https://doi.org/10.1101/113704; this version posted March 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Identification of drug candidates that enhance pyrazinamide activity from a clinical drug library Hongxia Niub, a, Chao Mac, Peng Cuid, Wanliang Shia, Shuo Zhanga, Jie Fenga, David Sullivana, Bingdong Zhu b, Wenhong Zhangd, Ying Zhanga,d* a Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA b Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China c College of Biological Sciences and Technology, Beijing Forestry University, Beijing 100083, China d Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China *Correspondence: Ying Zhang, E-Mail: [email protected] Tuberculosis (TB) remains a leading cause of morbidity and mortality globally despite the availability of the TB therapy. 1 The current TB therapy is lengthy and suboptimal, requiring a treatment time of at least 6 months for drug susceptible TB and 9-12 months (shorter Bangladesh regimen) or 18-24 months (regular regimen) for multi-drug-resistant tuberculosis (MDR-TB). 1 The lengthy therapy makes patient compliance difficult, which frequently leads to emergence of drug-resistant strains. The requirement for the prolonged treatment is thought to be due to dormant persister bacteria which are not effectively killed by the current TB drugs, except rifampin and pyrazinamide (PZA) which have higher activity against persisters.
    [Show full text]
  • Genetic Epidemiology and Preventive Healthcare in Multiethnic Societies: the Hemoglobinopathies
    Int. J. Environ. Res. Public Health 2014, 11, 6136-6146; doi:10.3390/ijerph110606136 OPEN ACCESS International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph Review Genetic Epidemiology and Preventive Healthcare in Multiethnic Societies: The Hemoglobinopathies Piero C. Giordano *, Cornelis L. Harteveld and Egbert Bakker Human and Clinical Genetics Department, Leiden University Medical Center, P.O. Box 9600, Leiden 2333 ZC, The Netherlands; E-Mails: [email protected] (C.L.H.); [email protected] (E.B.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +31-71-526-9800/+31-71-576-2341; Fax: +31-71-526-8276. Received: 25 March 2014; in revised form: 30 May 2014 / Accepted: 3 June 2014 / Published: 11 June 2014 Abstract: Healthy carriers of severe Hemoglobinopathies are usually asymptomatic and only efficiently detected through screening campaigns. Based upon epidemiological data, screenings have been offered for decades to populations of endemic Southern Europe for primary prevention of Thalassemia Major, while for many populations of the highly endemic African and Asian countries prevention for Sickle Cell Disease and Thalassemia Major is mainly unavailable. The massive migrations of the last decades have brought many healthy carriers of these diseases to live and reproduce in non-endemic immigration areas changing the epidemiological pattern of the local recessive diseases and bringing an urgent need for treatment and primary prevention in welfare countries. Nonetheless, no screening for an informed reproductive choice is actively offered by the healthcare systems of most of these welfare countries.
    [Show full text]
  • Risks to Health and the Environment Related to the Use of Mercury Products
    Ref. Ares(2015)4242228 - 12/10/2015 Risks to Health and the Environment Related to the Use of Mercury Products Final Report prepared for The European Commission, DG Enterprise by Risk & Policy Analysts Limited, Farthing Green House, 1 Beccles Road, Loddon, Norfolk, NR14 6LT Tel: 01508 528465 Fax: 01508 520758 Email: [email protected] Web: www.rpaltd.co.uk RPA REPORT - ASSURED QUALITY Project: Ref/Title J372/Mercury Approach: In accordance with the Contract, Scoping Meeting with the Commission and associated discussions Report Status: Final Report Authors: Dr P Floyd & P Zarogiannis, RPA Dr M Crane, Crane Consultants Prof S Tarkowski, Nofer Institute of Occupational Medicine (Poland) Prof V Bencko, Charles University of Prague Approved for Issue by: Ms M Postle, Director Date: 9 August, 2002 If printed by RPA, this report will be on chlorine free, 100% recycled paper. Risk & Policy Analysts EXECUTIVE SUMMARY Overview Mercury and its compounds are hazardous materials which may pose risks to people and to the environment. This report presents an assessment of the risks associated with the use of mercury in a range of products. The key requirements of the study were: • to identify usage of mercury in dental amalgam, batteries, measuring instruments (such as thermometers and manometers), lighting, other electrical components and other lesser uses; • to review data used to evaluate the toxicity of mercury and mercury compounds to humans and to the environment; • to derive predicted environmental concentrations (PECs) associated with use of the products under consideration and compare with those associated with other sources of mercury; and • to characterise the associated risks.
    [Show full text]
  • Survey of Mercury and Mercury Compounds
    Survey of mercury and mercury compounds Part of the LOUS-review Environmental Project No. 1544, 2014 Title: Authors and contributors: Survey of mercury and mercury compounds Jakob Maag Jesper Kjølholt Sonja Hagen Mikkelsen Christian Nyander Jeppesen Anna Juliana Clausen and Mie Ostenfeldt COWI A/S, Denmark Published by: The Danish Environmental Protection Agency Strandgade 29 1401 Copenhagen K Denmark www.mst.dk/english Year: ISBN no. 2014 978-87-93026-98-8 Disclaimer: When the occasion arises, the Danish Environmental Protection Agency will publish reports and papers concerning research and development projects within the environmental sector, financed by study grants provided by the Danish Environmental Protection Agency. It should be noted that such publications do not necessarily reflect the position or opinion of the Danish Environmental Protection Agency. However, publication does indicate that, in the opinion of the Danish Environmental Protection Agency, the content represents an important contribution to the debate surrounding Danish environmental policy. While the information provided in this report is believed to be accurate, the Danish Environmental Protection Agency disclaims any responsibility for possible inaccuracies or omissions and consequences that may flow from them. Neither the Danish Environmental Protection Agency nor COWI or any individual involved in the preparation of this publication shall be liable for any injury, loss, damage or prejudice of any kind that may be caused by persons who have acted based on their understanding of the information contained in this publication. Sources must be acknowledged. 2 Survey of mercury and mercury compounds Contents Preface ...................................................................................................................... 5 Summary and conclusions ......................................................................................... 7 Sammenfatning og konklusion ................................................................................ 14 1.
    [Show full text]
  • Key Features That Power Workflow Efficiency Here’S What the System Vendors and Users Have to Say
    Key Features that Power Workflow Efficiency Here’s what the system vendors and users have to say. story begins on page 13 Flip the Pharmacy Telepharmacy The New Normal 8 The New Direction for 31 The Potential 35 COVID-19’s Impact Pharmacy Benefits on Pharmacy How Vendors Aremay/june Meeting 2020 Pharmacy computer Needstalk During a Crisis 1 ® Be like Miral- frameworkltc.com 412-492-9841 [email protected] Save valuable time without losing valuable space. Do you need affordable and reliable tabletop counting technology but lack counter space? The RM1™ is a compact, vision-based tabletop counting system perfect for growing or space-limited pharmacies. The RM1 quickly and accurately counts solid oral medications, has an easy-to-clean surface and saves you valuable time without taking up scarce counter space. Less than 8 inches tall and lightweight at only six pounds, the RM1 packs efficiency and affordability into one powerful and portable automated counting system. See the future of pharmacy automation and what it can do for you. Visit rxmedic.com or call 800.882.3819. “It definitely improves our workflow efficiency and it’s very easy to use. We’ve tried other counters in the past and they didn’t work well for us. The RM1 works and it’s a great value. We have seven, one for each of our locations.” Miral Patel, RPh – Owner, Curlew Pharmacies, Clearwater, FL We’re here for you There are a lot of unknowns in the world right now. But one thing is certain — we still have patients to serve.
    [Show full text]